Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights

Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting

Results from the completed dose-escalation of the ALLOSHRINK phase I study evaluating the allogeneic NKG2D-based CAR T-cell therapy CYAD-101 in metastatic colorectal cancer patients

Results from the completed dose-escalation of the ALLOSHRINK phase I study evaluating the allogeneic NKG2D-based CAR T-cell therapy CYAD-101 in metastatic colorectal cancer patients

Effect of chemotherapy on cellular kinetics of NKG2D-based CAR T-cells in metastatic colorectal cancer patients

Effect of chemotherapy on cellular kinetics of NKG2D-based CAR T-cells in metastatic colorectal cancer patients

Results from the completed dose-escalation phase I SHRINK study evaluating the autologous NKG2D-based CAR T-cell therapy CYAD-01 in metastatic colorectal cancer patients

Results from the completed dose-escalation phase I SHRINK study evaluating the autologous NKG2D-based CAR T-cell therapy CYAD-01 in metastatic colorectal cancer patients

Celyad to Present Update to r/r AML and MDS Program at 2019 ASH Annual Meeting

Celyad to Present Update to r/r AML and MDS Program at 2019 ASH Annual Meeting

Celyad Highlights Abstracts from mCRC Clinical Program Released for SITC 34th Annual Meeting

Celyad Highlights Abstracts from mCRC Clinical Program Released for SITC 34th Annual Meeting

Celyad Announces October and November 2019 Investor Conference Schedule

Celyad Announces October and November 2019 Investor Conference Schedule

Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting

Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting

Celyad Announces Closing of $20 Million Global Offering

Celyad Announces Closing of $20 Million Global Offering

The targeted knockdown of CD3ζ by shRNA as a platform to develop allogeneic CAR T cell therapy

The targeted knockdown of CD3ζ by shRNA as a platform to develop allogeneic CAR T cell therapy